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ABSTRACT
Introduction: Opioid analgesics are widely
regarded to be highly effective but are equally
known for their side effects on the bowel. A new
combination of the opioid analgesic oxycodone
and naloxone has been developed to combat
opioid-induced bowel dysfunction (OIBD)
whilst still being effective as an analgesic. The
aim of this observational study was to assess the
analgesic efficacy of this new combination and
to analyze its effect on bowel function.
Methods: Twenty-six patients underwent a trial
of this new combination, with 21 patients
reaching week 8 and 18 reaching week 12.
Results: A significant reduction was seen in the
pain severity score at weeks 4, 8, and 12
(P\0.05), and a significant improvement in
the bowel function index was again seen at
these points (P\0.001 at week 4 and 12,
P\0.05 at week 8). In the patients’ global
impression of change, 83.3% of patients rated
the new medication as an improvement
compared to their previous regimen, and
87.5% rated it overall as ‘‘good’’ or ‘‘very good.’’
Conclusion: This small single-center study
suggests that the use of ONC in selected
patients could lead to an improvement in pain
severity and pain interference with a significant
improvement in OIBD. Compliance with the
combination is good, and it is generally well
tolerated.
Keywords: Naloxone; Opioid-induced bowel
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INTRODUCTION
Opioid analgesics are known to be highly
effective, but are equally known for their side
effects on the bowel. As an example of this, it
has been reported that around 41% of
non-cancer patients treated for pain report
constipation [1]. This constipation often
requires the administration of sometimes
multiple laxatives, which often do not
satisfactorily relieve it. A new oral
combination of oxycodone, an already proven
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and widely used analgesic, and naloxone in a
ratio of 2:1 to combat opioid-induced bowel
dysfunction (OIBD) is now available. Some of
the data in this study have previously been
published in abstract form in the proceedings of
the World Institute of Pain conference,
Maastricht, 2014, where it was featured in a
poster [2].
METHODS
Recruitment was from a population of patients
attending the chronic pain clinics at the Royal
Preston Hospital following a protocol (Fig. 1).
The oxycodone and naloxone combination
(ONC) was already a licensed preparation and
was approved by the Trust’s drug and
therapeutic committee for use within the trust
with the intent of monitoring its efficacy on a
small number of patients. As such, the sample
size was determined by the number of patients
who satisfied the protocol in the study period.
There were no age inclusion or exclusion
criteria. Twenty-six patients were recruited
over the period 28 June 2012 to 11 November
2013. The medication and study were
explained, and verbal informed consent to
continue was obtained. As a baseline, a brief
pain inventory as well as bowel function index
were collected by a clinician on a pro forma
designed by the Trust in conjunction with
NAPP Pharmaceuticals. The ONC was then
commenced as per the trust protocol (Fig. 1).
Data were collected weekly via telephone on
Fig. 1 Trust protocol for the initiation of the oxycodone and naloxone combination. NSAIDS nonsteroidal
anti-inﬂammatory drugs
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weeks 1, 2, 3, 5, 6, 7, 9, 10, and 11, which were
entered onto the same pro forma as data
collected in the clinic by a clinician on weeks
4 and 8 and at the end of the trial
(11–12 weeks).
The data were then collated onto a
spreadsheet for analysis, and descriptive
statistical analyses of the group variables were
calculated. The pain severity, pain interference,
and bowel function indexes were tested for
normality and compared using a paired
Student’s t test on SPSS (version 20; IBM
Corp., Armonk, NY, USA) [3]. Patients were
also asked to give the combination a rating at
the end of the trial, which included patients’
global impression of change (PGIC), general
rating, and a rating in comparison to their
previous analgesics, which were then analyzed
using descriptive statistics.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed verbal consent was obtained
from all patients for being included in the
study, and this methodology was approved by
Lancashire Teaching Hospitals NHS foundation
trust drug and therapeutic committee.
RESULTS
Twenty-six patients started the trial. The mean
(range) age of those starting the trial was
57.9 years (21–85 years). Eighteen patients
(69.2%) completed the trial. A range of sites
for the pain was represented in the sample; the
largest group [14 (53.8%)] had lower back pain
(±radiation), followed by widespread pain, leg
pain, and then hip pain. Other areas also
included the abdomen, perineum, thoracic
region, hands, and coccyx. Twenty-five
(96.2%) patients were taking opioid analgesia
prior to the ONC, 11 (42.3%) of whom were
taking strong opioid analgesia (oxycodone,
morphine sulfate, fentanyl patch,
buprenorphine patch), 13 (50%) were taking a
weak opioid (tramadol, codeine or
dihydrocodeine), and 1 patient was taking
paracetamol only (due to OIBD). Twenty-two
(84.6%) patients were taking laxatives at
therapeutic levels, with 5 (19.2%) patients
taking 2 different laxatives and 3 (11.5%)
patients taking 3. A more detailed breakdown
is available in Table 1.
For weeks 4 and 8, 21 patients had data for
analysis. The pain severity score [standard
deviation (SD)] was significantly lower than
baseline 6.9 (1.2) to 6.0 (1.9) at week 4 (P\0.05)
and 5.6 (2.2) at week 8 (p\0.05). A reduction
was also seen in the pain interference score (SD)
from 7.0 (1.5) at baseline to 6.2 (2.1) at week 4
(P[0.05) and 5.6 (2.3) at week 8 (P\0.05). The
bowel function index (SD) dropped from an
average of 69.7 (25.6) to 42.8 (31.9) at week 4
(P\0.001) and to 46.6 (35.2) at week 8
(P\0.05). The average starting dose (range)
was 10.6 mg (5–40 mg) and the average dose
(range) at the end of trial was 16.3 mg
(5–40 mg). Thirteen (50.0%) patients required
an increase in dose during the trial, of whom 7
(26.9%) required an increase of C10 mg and 2
(7.7%) required an increase of C20 mg.
Of 26 patients, a total of 18 had trial end data
for analysis. The pain severity score (SD) was
significantly lower than baseline 6.9 (1.4) at 5.4
(2.5; P\0.05), the pain interference score (SD)
7.1 (1.7) to 5.5 (2.3; P\0.05), and the bowel
function index (SD) from 73.1 (26.8) to 35.6
(39.1; P\0.001). Where stated, the main reason
for discontinuation was intolerance of side
effects. Side effects were reported by six
(23.1%) patients during the trial, which
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included sleep disturbance (nightmares and
moving during sleep; n = 1), leg swelling/dry
mouth (n = 1), agitation (jumpy/twitchy feeling
described, particularly at a point where a dose is
wearing off; n = 1), and cognition (n = 1) and
mood changes (including mood lability,
‘‘dramatic mood changes,’’ and mood swings;
n = 2). Two of these patients had loss of
inhibition after starting ONC necessitating its
discontinuation, one of which was punching
during their sleep.
In the PGIC, 15 of 18 (83.3%) patients rated
the medication as an improvement, with 10
(55.6%) stating ‘‘much improved’’ or ‘‘very
much improved’’ (Fig. 2). Eleven of 18 (61.1%)
patients scored the combination as being better
than their previous medications, 6 (33.3%) as
the same and 1 (5.6%) as worse (Fig. 3). Patients
were also asked to give a general rating, with 14
of 18 (87.5%) patients rating the combination
as very good (n = 9) or good (n = 5), 3 patients
could not decide between good and bad, and 1
patient rated it as bad.
DISCUSSION
This study is a small single-center assessment of
the initial use of this new combination within a
Trust protocol. The sample size is small because
of the timeframe and the strict protocol used,
which makes it difficult to draw concrete
conclusions. However, it did indicate that the
combination could give superior analgesia with
less OBID. This reduction in OIBD whilst
providing effective analgesia with ONC has
also been observed in a number of other
studies [4–11] adding more evidence to
support the efficacy of the combination in the
reduction of OIBD. The numeric reduction in
BFI has also been seen previously [5, 7]. The
superior analgesic effects observed in this study
could be attributed to a number of factors. First,
this was not a case-control type study like a
number of the studies referenced above and the
two were not directly compared. Second, all of
the studies mentioned above compared the
combination to oxycodone, whereas this
Table 1 Detailed breakdown of pre-study medications
Analgesia prior to study N Laxative prior to study N
Paracetamol 1 None 4
Co/codamol 6 Senna 3
Dihydrocodeine/codeine phosphate 4 Macrogol 4
Tramadol 3 Lactulose 4
Tramadol and co-codamol 1 Ipsaghula husk 3
Bupenorphrine 4 Senna and macrogol 3
Bupenorphrine/co-codamol 1 Senna and bisacodyl 1
Bupenorphrine/morphine sulphate 1 Lactulose and ipsaghula husk 1
Fentanyl patch/co-codamol 1 Docusate, senna, and prucalopride 1
Morphine modiﬁed release 1 Senna, macrogol, and lactulose 1
Oxycodone 2 Senna, ipsaghula husk, and lactulose 1
Oxycodone/tramadol 1
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group drew comparison with the patient’s
previous analgesia, which ranged from no
analgesia to other opioid medications. As
such, it could be suggested that the ONC is
comparable in terms of analgesia to oxycodone
and superior to other regimes, with an
improvement in OIBD. Another factor that
must be taken into account is the effect of
OIBD on compliance. It was seen in this study
that a number of patients were taking little or
no analgesia through fear of OIBD and as a
result were receiving inadequate analgesia. The
introduction of this combination has allowed
them to receive effective analgesia without
OIBD. This can also be seen in patient ratings
such as comparison to previous medication.
More detailed collection of pre-trial medication
data such as dose and actual compliance would
have allowed a more robust comparison.
The patient ratings of the combination also
revealed that it is effective. This study showed
that a majority of patients feel that it is ‘‘good’’
or ‘‘very good’’. This has again been seen in
another study that saw 50.0–72.5% of patients
rating the combination as good or very good
(range dependent on the dose) [12]. The
combination was better tolerated in this study
with the incidence of side effects lower at 23.1%
than other studies, which saw rates of 55.8% [8]
and 55.8% [4]; however, this could reflect the
length of follow-up or smaller sample size.
CONCLUSIONS
This is a single-center observational study with
small sample size. It suggested that the use of
ONC in selected patients could lead to an
improvement in pain severity and pain
interference with a significant improvement in
OIBD. Compliance with ONC is good, and less
than one quarter of patients reported side
effects. Most patients rated the combination as
very good and found it better than their
previous medications. The majority of the
patients on ONC had an improvement in their
condition. The results of this study could be
used to assist the design of a larger, perhaps
multicenter study or the data could be pooled
for analysis.
ACKNOWLEDGMENTS
With thanks to the following who completed
data collection and consolidation during the
study: Sharon Gilbert, Clinical Nurse Specialist
in Chronic Pain, Lancashire Teaching Hospitals




















Fig. 2 Patient global impression of change rating
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